Thursday, 22 Jun 2017

You are here

Guselkumab for Active Psoriatic Arthritis

A double-blind, placebo-controlled, multicenter study aimed to evaluate efficacy and safety of a fully human monoclonal anti IL-23 antibody guselkumab (GUS), in patients with active psoriatic arthritis (PsA).  

Patients with active PsA and ≥3% body surface area of plaque psoriasis, both bio-naive and TNF experienced, were randomized 2:1 to receive GUS 100 mg subcutaneously (SC) or placebo (PBO) as follows:

 

  

Significant amount of patients in the treatment group achieved ACR 20 as early as week 4 (21% vs 0, p<0.001) and primary endpoint of ACR 20 response at wk24 was met in 58% of GUS patients RA as opposed to 18.4% in placebo group. Major secondary endpoints were PASI 75 and ACR 50 responses, change from baseline in HAQ-DI, and improvement in enthesitis (Leeds enthesitis index) and dactylitis score (by a 0–3 scoring system) at wk24 and were all significantly better in GUS group.

 

 

 

One patient in GUS groups developed grade 3 neutropenia that resolved after discontinuation of treatment. Infections were the most common AEs (PBO: 20.4%; GUS: 17.0%, respectively).

 

Overall, study concluded GUS demonstrated significant improvement of arthritis, psoriasis, enthesitis, dactylitis and quality of life and was well tolerated with no unexpected safety signals.

Add new comment

More Like This

EULAR 2017 – Day 4 Highlights

Saturday was a day of big posters and special seminars at EULAR in Madrid.  In the morning, I passed on an interesting session on nailfold capillaroscopy led by Dr. M Cutolo and went to a JIA outcomes session. I reported on this in a video from day 4 (Saturday) called “Long-Term Comorbidities in JIA” – you can find it here.

Responder Criteria for Nonpharmalogical Treatment of Fibromyalgia.

Because of the subjective nature of fibromyalgia symptoms, tools for monitoring of disease activity and/or treatment assessment tools to evaluate effectiveness of nonpharmacological modalities are difficult to develop.

Concomitant Septic Arthritis and Crystalline Arthropathy

Researchers sought to describe the characteristics of patients with concurrent septic and crystal arthritis through a retrospective analysis of patients with the concomitant diagnoses between 1985-2015 at a university hospital in Spain.

EULAR 2017 – Day 3 Highlights

Friday was a mega-day in Madrid as this day all the late-breaking abstracts were presented, in addition to the bulk of high-impact podium presentations in several areas.

Here are the major presentations from several clinical areas.

Herpes Zoster

Today during the comorbidities in RA session, Dr. Leonard Calabrese spoke about herpes zoster (HZ). Given the frequency of HZ in immunocompetent persons and the fact that patients with IMIDs carry at least twice the risk of developing HZ, it is important for rheumatologists to be informed about diagnosis, treatment and most importantly prevention of HZ.